Navigation Links
China Medical Technologies Reports Financial Results for Fourth Fiscal Quarter and Full Year ended March 31, 2010
Date:6/4/2010

class="xn-money">RMB89.7 million was allocated to cost of revenues and RMB109.4 million to operating expenses.

For the convenience of readers, certain RMB amounts have been translated into U.S. dollars at the rate of RMB6.8258 to US$1.00, the noon buying rate in New York City for cable transfers of RMB per U.S. dollar as set forth in the H.10 weekly statistical release of the Federal Reserve Board, as of Wednesday, March 31, 2010. No representation is made that the RMB amounts could have been or could be converted into U.S. dollars at that rate or at any other rate on March 31, 2010 or at any other dates.

Share Repurchase Program

In September 2009, the Company's board of directors authorized a share repurchase program, under which the Company may repurchase up to US$30 million worth of its outstanding ADSs from the open market or in block trades for a period of one year, commencing on October 1, 2009. As of March 31, 2010, the Company repurchased a total of 500,000 ADSs at a cost of approximately US$6.4 million (including transaction costs). The Company has terminated the program.

Convertible Notes

The Company purchased 4% convertible notes with principal amount of about RMB76.8 million (US$11.2 million) for a total consideration of RMB50.5 million (US$7.4 million) during 4Q FY2009. As of March 31, 2010, the Company had '/>"/>

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek ... that it has initiated the development of its lead ... and that it has selected Quotient Clinical, The Translational ... (UK) to run its early development programs. ... Trial Application (CTA) by the end of the third ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
... SAN DIEGO, Jan. 31 TargeGen, Inc. ... multi-center Phase I/II clinical trial of,TG101348, an ... JAK2 in,patients with myeloproliferative diseases., (Logo: ... of JAK2 is implicated in the pathogenesis ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Cached Medicine Technology:TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
(Date:8/1/2014)... 01, 2014 The North America Sports Drink ... North America, with analysis and forecast of revenue. The Sports ... around $5,021.9 million in 2012 to $6,243 million by 2018, ... Browse through the TOC of the North America Sports Drink ... provided. This also provides a glimpse of the segmentation in ...
(Date:8/1/2014)... Society of America (GSA) the nation,s largest ... has chosen Sean P. Curran, PhD, of the University ... Nathan Shock New Investigator Award. , This distinguished honor ... aging through basic biological research. It was established in ... of GSA and pioneer in gerontological research at the ...
(Date:8/1/2014)... of electronic reminders such as text messages, emails or ... adhere to a preadmission antiseptic showering regimen known to ... to a first-of-its-kind study published in the August issue ... Surgeons . , Each year approximately 400,000 SSIs occur ... according to data sources cited by study authors. ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Chilton ... portal that aims to empower patients and their ... their health care by providing easy, secure access ... gives patients instant, web-based access to their health ... radiology results, medications, allergies, demographic information, visit history, ...
(Date:8/1/2014)... NY (PRWEB) August 01, 2014 Ticket Down ... at Maple Lane Farms in Knoxville/Greenback, TN; Ingram Farms ... Whitehurst Cattle Farm in Archer/Gainesville, FL. Luke Bryan is currently ... with Lee Brice and Cole Swindell. Bryan is responsible for ... world each summer and this year, just because the summer ...
Breaking Medicine News(10 mins):Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Sports Drinks Market is Expected to Reach $6,243 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Curran to receive GSA's 2014 Nathan Shock New Investigator Award 2Health News:Electronic reminders can help patients prevent surgical site infections 2Health News:Electronic reminders can help patients prevent surgical site infections 3Health News:Chilton Medical Center Launches Online Patient Portal 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 2Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 3Health News:Luke Bryan Tickets at Maple Lane Farms in Knoxville, Ingram Farms in Auburn, Cross Creek Place in Tallahassee & Whitehurst Cattle Farm in Gainesville Now Available 4
... Eliminates Need for Cadavers and Accelerates Physician TrainingGREAT ... maker of anatomically accurate surgical training models, is ... new Maxillary Clinical Sinus Trainer. This innovative ... to train ENT surgeons on their new FinESS(TM) ...
... is a Gift that Helps Doctors Improve Health CareWINSTON-SALEM, N.C., ... 30th, DrScore.com , the physician rating Web ... feedback by rating their doctors online. "The best gift patients ... in general is honest, constructive feedback," says Steve Feldman M.D., ...
... in French . , Montreal, March ... to reality, thanks to a discovery from scientists at ... According to a study published in the journal ... first to clone, produce and purify a protein important ...
... incisionless, non-invasive procedure treats patients with chronic reflux ... Center today announced that two surgeons from its ... Washington State on Monday, March 16. EsophyX ... gastroesophageal reflux disease, or GERD. The two ...
... What can you buy with a dollar anymore? ... and treatment for those who cannot afford to battle breast ... Brandon Mendelson and the 1 in 8 Foundation are challenging ... $1 and provide care and complete support for women and ...
... on factory farmsWASHINGTON, March 17 Nearly one year ... released its landmark recommendations on how America should reform ... Slaughter today introduced the Preservation of Antibiotics for Medical ... the Federal Food, Drug, and Cosmetic Act to withdraw ...
Cached Medicine News:Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 2Health News:Chamberlain Group Surgical Training Model Facilitates New Treatment for Chronic Rhinosinusitis 3Health News:Rate Your Doctor at DrScore.com for Doctor's Day 2Health News:Rate Your Doctor at DrScore.com for Doctor's Day 3Health News:Researchers clone key sperm-binding proteins 2Health News:Northwest Hospital Surgeons Perform First EsophyX Procedure in Washington State 2Health News:$1 Can Make The Difference 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 2Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 3Health News:Pew Applauds Introduction of Preservation of Antibiotics for Medical Treatment Act 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: